Amgen/UCB's Phase III Success May Not Be Enough To Top Osteoporosis Rivals
This article was originally published in The Pink Sheet Daily
Executive Summary
Romosozumab shows ability to reduce risk of spinal fractures, but misses a secondary endpoint on nonvertebral fracture risk reduction.